NASDAQ:HUGE

FSD Pharma Competitors

$1.56

-0.03 (-1.89 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.52

Now: $1.56▼

$1.62

50-Day Range

$1.59

MA: $1.96▼

$2.39

52-Week Range

$1.28

Now: $1.56▼

$14.00

Volume708,662 shs

Average Volume3.66 million shs

Market Capitalization$29.89 million

P/E RatioN/A

Dividend YieldN/A

Beta1.39

FSD Pharma (NASDAQ:HUGE) Vs. CGC, APHA, CRON, TLRY, USNA, and ACB

Should you be buying HUGE stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to FSD Pharma, including Canopy Growth (CGC), Aphria (APHA), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), and Aurora Cannabis (ACB).

FSD Pharma vs. Canopy Growth Stock

Canopy Growth (NASDAQ:CGC) and FSD Pharma (NASDAQ:HUGE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Volatility & Risk

Canopy Growth has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Earnings & Valuation

This table compares Canopy Growth and FSD Pharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$297.34 million	35.73	$-993,370,000.00	$1.32	21.06
FSD Pharma	$190,000.00	157.33	$-39,200,000.00	($5.55)	-0.28

FSD Pharma has lower revenue, but higher earnings than Canopy Growth. FSD Pharma is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 0.7% of FSD Pharma shares are held by institutional investors. 0.3% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Canopy Growth and FSD Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-312.84%	-13.11%	-9.66%
FSD Pharma	N/A	-111.76%	-92.92%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Canopy Growth and FSD Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	5	10	2	1	1.94
FSD Pharma	0	0	1	0	3.00

Canopy Growth currently has a consensus price target of $35.6778, indicating a potential upside of 28.34%. Given FSD Pharma's stronger consensus rating and higher probable upside, analysts clearly believe FSD Pharma is more favorable than Canopy Growth.

Summary

Canopy Growth beats FSD Pharma on 9 of the 15 factors compared between the two stocks.

FSD Pharma vs. Aphria Stock

FSD Pharma (NASDAQ:HUGE) and Aphria (NASDAQ:APHA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Institutional and Insider Ownership

0.7% of FSD Pharma shares are owned by institutional investors. Comparatively, 10.3% of Aphria shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

FSD Pharma has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, indicating that its stock price is 167% more volatile than the S&P 500.

Profitability

This table compares FSD Pharma and Aphria's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FSD Pharma	N/A	-111.76%	-92.92%
Aphria	-36.10%	-2.30%	-1.66%

Analyst Ratings

This is a summary of recent ratings for FSD Pharma and Aphria, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FSD Pharma	0	0	1	0	3.00
Aphria	0	5	3	0	2.38

Aphria has a consensus target price of $22.00, indicating a potential upside of 55.59%. Given FSD Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe FSD Pharma is more favorable than Aphria.

Earnings & Valuation

This table compares FSD Pharma and Aphria's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FSD Pharma	$190,000.00	157.33	$-39,200,000.00	($5.55)	-0.28
Aphria	$405.96 million	11.03	$-63,210,000.00	($0.06)	-235.67

FSD Pharma has higher earnings, but lower revenue than Aphria. Aphria is trading at a lower price-to-earnings ratio than FSD Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Aphria beats FSD Pharma on 7 of the 13 factors compared between the two stocks.

FSD Pharma vs. Cronos Group Stock

Cronos Group (NASDAQ:CRON) and FSD Pharma (NASDAQ:HUGE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cronos Group and FSD Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	2	4	1	0	1.86
FSD Pharma	0	0	1	0	3.00

Cronos Group presently has a consensus price target of $8.75, indicating a potential upside of 4.67%. Given FSD Pharma's stronger consensus rating and higher probable upside, analysts clearly believe FSD Pharma is more favorable than Cronos Group.

Earnings & Valuation

This table compares Cronos Group and FSD Pharma's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$25.64 million	117.46	$1.17 billion	$0.67	12.48
FSD Pharma	$190,000.00	157.33	$-39,200,000.00	($5.55)	-0.28

Cronos Group has higher revenue and earnings than FSD Pharma. FSD Pharma is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cronos Group has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Institutional & Insider Ownership

11.8% of Cronos Group shares are held by institutional investors. Comparatively, 0.7% of FSD Pharma shares are held by institutional investors. 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Cronos Group and FSD Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cronos Group	266.31%	-1.61%	-1.41%
FSD Pharma	N/A	-111.76%	-92.92%

Summary

Cronos Group beats FSD Pharma on 10 of the 13 factors compared between the two stocks.

FSD Pharma vs. Tilray Stock

Tilray (NASDAQ:TLRY) and FSD Pharma (NASDAQ:HUGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Volatility & Risk

Tilray has a beta of 3.12, meaning that its stock price is 212% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Institutional and Insider Ownership

12.6% of Tilray shares are owned by institutional investors. Comparatively, 0.7% of FSD Pharma shares are owned by institutional investors. 16.8% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Tilray and FSD Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray	1	9	0	0	1.90
FSD Pharma	0	0	1	0	3.00

Tilray presently has a consensus target price of $18.3078, indicating a potential upside of 6.44%. Given FSD Pharma's stronger consensus rating and higher possible upside, analysts plainly believe FSD Pharma is more favorable than Tilray.

Profitability

This table compares Tilray and FSD Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tilray	-242.60%	-92.70%	-20.70%
FSD Pharma	N/A	-111.76%	-92.92%

Valuation and Earnings

This table compares Tilray and FSD Pharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray	$166.98 million	17.69	$-321,170,000.00	($1.69)	-10.18
FSD Pharma	$190,000.00	157.33	$-39,200,000.00	($5.55)	-0.28

FSD Pharma has lower revenue, but higher earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than FSD Pharma, indicating that it is currently the more affordable of the two stocks.

FSD Pharma vs. USANA Health Sciences Stock

FSD Pharma (NASDAQ:HUGE) and USANA Health Sciences (NYSE:USNA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares FSD Pharma and USANA Health Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FSD Pharma	N/A	-111.76%	-92.92%
USANA Health Sciences	10.57%	32.91%	22.26%

Risk & Volatility

FSD Pharma has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Institutional & Insider Ownership

0.7% of FSD Pharma shares are owned by institutional investors. Comparatively, 54.1% of USANA Health Sciences shares are owned by institutional investors. 45.4% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares FSD Pharma and USANA Health Sciences' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FSD Pharma	$190,000.00	157.33	$-39,200,000.00	($5.55)	-0.28
USANA Health Sciences	$1.06 billion	1.92	$100.53 million	$4.41	22.42

USANA Health Sciences has higher revenue and earnings than FSD Pharma. FSD Pharma is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for FSD Pharma and USANA Health Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FSD Pharma	0	0	1	0	3.00
USANA Health Sciences	0	0	2	0	3.00

USANA Health Sciences has a consensus target price of $126.00, suggesting a potential upside of 27.41%. Given FSD Pharma's higher probable upside, research analysts clearly believe FSD Pharma is more favorable than USANA Health Sciences.

Summary

USANA Health Sciences beats FSD Pharma on 10 of the 13 factors compared between the two stocks.

FSD Pharma vs. Aurora Cannabis Stock

Aurora Cannabis (NYSE:ACB) and FSD Pharma (NASDAQ:HUGE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Aurora Cannabis and FSD Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	6	9	0	0	1.60
FSD Pharma	0	0	1	0	3.00

Aurora Cannabis currently has a consensus price target of $10.9264, suggesting a potential upside of 38.66%. Given FSD Pharma's stronger consensus rating and higher probable upside, analysts clearly believe FSD Pharma is more favorable than Aurora Cannabis.

Earnings and Valuation

This table compares Aurora Cannabis and FSD Pharma's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$207.89 million	7.50	$-2,468,190,000.00	($2.86)	-2.76
FSD Pharma	$190,000.00	157.33	$-39,200,000.00	($5.55)	-0.28

FSD Pharma has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than FSD Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aurora Cannabis and FSD Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-1,238.94%	-16.32%	-13.12%
FSD Pharma	N/A	-111.76%	-92.92%

Risk & Volatility

Aurora Cannabis has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Institutional & Insider Ownership

11.9% of Aurora Cannabis shares are held by institutional investors. Comparatively, 0.7% of FSD Pharma shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Aurora Cannabis beats FSD Pharma on 7 of the 13 factors compared between the two stocks.